NO20005399L - Farmasöytisk preparat - Google Patents

Farmasöytisk preparat

Info

Publication number
NO20005399L
NO20005399L NO20005399A NO20005399A NO20005399L NO 20005399 L NO20005399 L NO 20005399L NO 20005399 A NO20005399 A NO 20005399A NO 20005399 A NO20005399 A NO 20005399A NO 20005399 L NO20005399 L NO 20005399L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
NO20005399A
Other languages
English (en)
Other versions
NO20005399D0 (no
Inventor
Rinta Ibuki
Hideo Seki
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Masayuki Yamanaka
Erika Yoshida
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20005399L publication Critical patent/NO20005399L/no
Publication of NO20005399D0 publication Critical patent/NO20005399D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20005399A 1998-04-27 2000-10-26 Farmasøytisk preparat NO20005399D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27
PCT/JP1999/002237 WO1999055332A1 (en) 1998-04-27 1999-04-26 Medicinal compositions

Publications (2)

Publication Number Publication Date
NO20005399L true NO20005399L (no) 2000-10-26
NO20005399D0 NO20005399D0 (no) 2000-10-26

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005399A NO20005399D0 (no) 1998-04-27 2000-10-26 Farmasøytisk preparat

Country Status (24)

Country Link
US (2) US6673808B1 (no)
EP (1) EP1074255B1 (no)
JP (1) JP3732525B2 (no)
KR (1) KR100406823B1 (no)
CN (1) CN1161117C (no)
AR (1) AR018330A1 (no)
AT (1) ATE363275T1 (no)
AU (1) AU749475B2 (no)
BR (1) BR9910336A (no)
CA (1) CA2326222C (no)
DE (1) DE69936195T2 (no)
ES (1) ES2284248T3 (no)
HK (1) HK1038884B (no)
HU (1) HUP0104452A3 (no)
ID (1) ID29262A (no)
IL (1) IL139210A (no)
NO (1) NO20005399D0 (no)
NZ (1) NZ507345A (no)
PL (1) PL343627A1 (no)
RU (1) RU2203058C2 (no)
TR (1) TR200003108T2 (no)
TW (1) TW565461B (no)
WO (1) WO1999055332A1 (no)
ZA (1) ZA200005378B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
EP3342411B1 (en) * 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin derivative for treating pancreas cancer
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4579920B2 (ja) * 2004-06-24 2010-11-10 興和株式会社 アトルバスタチン外用剤組成物
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
PT1872783E (pt) * 2005-04-21 2012-01-16 Santen Pharmaceutical Co Ltd Agente terapêutico para distúrbio queratoconjuntivo
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
CN102176913B (zh) * 2008-10-08 2014-08-13 高田制药株式会社 外用的他克莫司制剂
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
CA3165081A1 (en) * 2020-01-24 2021-07-29 Toru Yasuzawa External preparation containing rapamycin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (no) * 1987-11-09 1991-05-31 Sandoz Ag
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
WO1991013889A1 (en) * 1990-03-13 1991-09-19 Fisons Plc Immunosuppressive macrocyclic compounds
JPH05507915A (ja) * 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW213418B (no) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
EP0978288A4 (en) * 1997-04-11 2006-07-12 Astellas Pharma Inc DRUG COMPOSITION

Also Published As

Publication number Publication date
IL139210A (en) 2005-11-20
CA2326222C (en) 2008-09-23
TW565461B (en) 2003-12-11
CA2326222A1 (en) 1999-11-04
CN1161117C (zh) 2004-08-11
BR9910336A (pt) 2001-09-25
PL343627A1 (en) 2001-08-27
EP1074255A4 (en) 2002-02-13
DE69936195T2 (de) 2007-09-13
WO1999055332A1 (en) 1999-11-04
WO1999055332A8 (en) 2000-02-17
US6673808B1 (en) 2004-01-06
ATE363275T1 (de) 2007-06-15
CN1307475A (zh) 2001-08-08
KR100406823B1 (ko) 2003-11-21
TR200003108T2 (tr) 2001-02-21
US20020061907A1 (en) 2002-05-23
HK1038884B (zh) 2005-05-06
IL139210A0 (en) 2001-11-25
KR20010042589A (ko) 2001-05-25
ES2284248T3 (es) 2007-11-01
JP3732525B2 (ja) 2006-01-05
RU2203058C2 (ru) 2003-04-27
HK1038884A1 (en) 2002-04-04
NO20005399D0 (no) 2000-10-26
ID29262A (id) 2001-08-16
ZA200005378B (en) 2002-08-23
NZ507345A (en) 2002-12-20
EP1074255B1 (en) 2007-05-30
AR018330A1 (es) 2001-11-14
DE69936195D1 (de) 2007-07-12
HUP0104452A2 (hu) 2002-03-28
AU749475B2 (en) 2002-06-27
AU3537299A (en) 1999-11-16
US6586444B2 (en) 2003-07-01
HUP0104452A3 (en) 2004-05-28
EP1074255A1 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
NO20005399L (no) Farmasöytisk preparat
NO20001612D0 (no) Oralt preparat
NO20030418D0 (no) Nytt farmasöytisk preparat
NO992339L (no) Farmasöytiske formuleringer
NO20001160L (no) Nytt skumdannende farmasøytisk preparat
ID27415A (id) Komposisi farmaseutik
NO983624D0 (no) Biocid preparat i fast form
ID29089A (id) Sediaan farmasi moksifloksasin
NO996372D0 (no) Fast farmasoeytisk preparat inneholdende benzofuanderivater
DK1466615T3 (da) Farmaceutisk præparat
EE200200150A (et) Preparaat
NO20015149L (no) Nytt farmasöytisk preparat
ID27201A (id) Komposisi farmasi
NO20015148L (no) Nytt farmasöytisk preparat
NO20011281D0 (no) Insekticid preparat
ID30032A (id) Formulasi farmasi
NO995039L (no) Gastrisk bibeholdt farmasoeytisk preparat
NO20015104D0 (no) Nytt farmasöytisk preparat
NO20015105L (no) Nytt farmasöytisk preparat
FI951155A0 (fi) Farmaseuttinen valmiste
ID26215A (id) Komposisi farmasi
NO20021036L (no) Farmasöytisk preparat
NO20011313D0 (no) Nytt preparat
NO20022541D0 (no) Fast preparat
NO20011312D0 (no) Nytt preparat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application